Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
06:00am, Wednesday, 03'rd Jun 2026
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RA
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
05:12pm, Tuesday, 02'nd Jun 2026
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Roche Holding (RHHBY) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 02'nd Jun 2026
Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
12:11pm, Tuesday, 02'nd Jun 2026
RHHBY's giredestrant as an adjuvant treatment for early-stage breast cancer won FDA Priority Review, backed by encouraging phase III data versus standard therapy.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--FDA accepts NDA for Genentech's giredestrant in ER+ early-stage breast cancer.
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy1
Basel, 02 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (US) Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under Prio
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
10:02am, Monday, 01'st Jun 2026
This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical companies, with no major plenary presentations and little data capable of movi
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
01:00am, Monday, 01'st Jun 2026
Late-breaking Phase II data highlight enicepatide's (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overwei
Roche to present new data advancing its obesity portfolio at the American Diabetes Association's 2026 Scientific Sessions
01:00am, Monday, 01'st Jun 2026
Basel, 1 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association�
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions
01:00am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 202
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
06:17am, Wednesday, 27'th May 2026
Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic'
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
01:00am, Wednesday, 27'th May 2026
Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO-a certified algorithm de
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
12:40pm, Monday, 25'th May 2026
AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
03:35pm, Wednesday, 20'th May 2026
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
